John A. Jernigan*, David S. Stephens*†, David A. Ashford*, Carlos Omenaca‡, Martin S. Topiel§, Mark Galbraith¶, Michael Tapper#, Tamara L. Fisk*†, Sherif Zaki*, Tanja Popovic*, Richard F. Meyer*, Conrad P. Quinn*, Scott A. Harper*, Scott K. Fridkin*, James J. Sejvar*, Colin W. Shepard*, Michelle McConnell*, Jeannette Guarner*, Wun-Ju Shieh*, Jean M. Malecki**, Julie L. Gerberding*, James M. Hughes*, Bradley A. Perkins*, and members of the Anthrax Bioterrorism Investigation Team
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA;; †Emory University School of Medicine, Atlanta, Georgia, USA;; ‡Cedars Medical Center, Miami, Florida, USA;; §Virtua Health, Mount Holly, New Jersey, USA;; ¶Winchester Medical Center, Winchester, Virginia, USA;; #Lenox Hill Hospital, New York City, New York, USA;; **Palm Beach County Department of Public Health, West Palm Beach, Florida, USA
Article in English
l'Article Principal
Tableau 2
Symptoms for 10 patients with bioterrorism-related inhalational anthrax, October - November 2001
|
Symptômes |
n=10 |
|
Fièvre, frissons |
10 |
|
Sueurs, souvent profuses |
7 |
|
Fatigue, malaise, léthargie |
10 |
|
Toux (légère ou improductive) |
9 |
|
Nausées ou vomissements |
9 |
|
Dyspnée |
8 |
|
Gêne thoracique ou douleurs de type pleurétique |
7 |
|
Myalgies |
6 |
|
Maux de tête |
5 |
|
Etat confusionnel |
4 |
|
Douleurs abdominales |
3 |
|
Maux de gorge |
2 |
|
Rhinorrhée |
1 |
l'Article Principal
Haut de Page